Application Value of Dexmedetomidine Combined with Thoracic Paravertebral Block in Fast-track Anesthesia for Thoracoscopic Heart Valve Replacement Surgery

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114342

Enrollment

Unknown

Registered

2025-12-10

Start date

2025-12-16

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

valvular heart disease

Interventions

dexmedetomidine group:Dexmedetomidine as an adjuvant for thoracic paravertebral nerve block

control group:none

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. All patients underwent thoracoscopic cardiac valve surgery; 2. Age >=18 years; 3. American Society of Anaesthesiologists (ASA) physical status classification III–IV; 4. New York Heart Association (NYHA) functional class III or below; 5. Informed consent obtained, with voluntary participation in this study.

Exclusion criteria

Exclusion criteria: 1. NYHA Class IV heart failure; 2. Pulmonary hypertension; 3. Complex aortic root surgery; 4. Patients undergoing deep hypothermia extracorporeal circulation; 5. Patients with local anaesthetic allergy; 6. Pregnant women.

Design outcomes

Primary

Measure	Time frame
postoperative extubation time;	—

Secondary

Measure	Time frame
perioperative opioid consumption;ICU length of stay;length of stay;	—

Countries

China

Contacts

Public ContactYuan Binglin

Zhongshan People's Hospital

yuanbinglin66@163.com+86 137 9072 6063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026